Fosrenol (Lanthanum)

lanthanum 1 g chewable tablet, 6 x 15 · ORAL · PBS code 9405B

STREAMLINED

What it costs

AU$281.17 PBS-determined price per 90 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2009-05-01.
• Repeats: 5.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Hyperphosphataemia

Maintenance following initiation and stabilisation

The condition must not be adequately controlled by calcium; AND

Patient must have a serum phosphate of greater than 1.6 mmol per L at the commencement of therapy; or

The condition must be where a serum calcium times phosphate product is greater than 4 at the commencement of therapy; AND

The treatment must not be used in combination with any other non-calcium phosphate binding agents; AND

Patient must be undergoing dialysis for chronic kidney disease.

Sponsor: Takeda Pharmaceuticals Australia Pty. Ltd. ABN 71 095 610 870

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.